Macro Group Pharmaceuticals (Macro Capital) S.A.E (EGX:MCRO)
Egypt · Delayed Price · Currency is EGP 1.590
+0.020 (1.27%)
At close: Oct 4, 2026
EGX:MCRO Income Statement
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 982.42 | 894.54 | 519.97 | 526.01 | 729.61 | 594.26 | |
Revenue Growth | 52.35% | 72.04% | -1.15% | -27.91% | 22.78% | 38.04% |
Cost of Revenue | 299.91 | 285.3 | 196.85 | 230.36 | 167.97 | 120.39 |
Gross Profit | 682.51 | 609.24 | 323.12 | 295.65 | 561.64 | 473.87 |
Selling, General & Admin | 488.68 | 428.35 | 274.82 | 353.03 | 314.18 | 256.02 |
Other Operating Expenses | 15.78 | 15.86 | 0.59 | 26.57 | 9.96 | 13.73 |
Operating Expenses | 534.04 | 473.79 | 311.09 | 478.04 | 327.29 | 270.25 |
Operating Income | 148.47 | 135.45 | 12.03 | -182.39 | 234.35 | 203.62 |
Interest Expense | -34.98 | -34.43 | -60.65 | -29.48 | -13.48 | -8.15 |
Interest & Investment Income | 9.39 | 9.39 | 5.77 | 1.98 | 2.8 | 1.06 |
Currency Exchange Gain (Loss) | 11.48 | 11.48 | - | 14.23 | 3.68 | -0.06 |
Other Non Operating Income (Expenses) | 9.33 | - | - | -49.95 | - | - |
EBT Excluding Unusual Items | 143.69 | 121.89 | -42.85 | -245.62 | 227.35 | 196.46 |
Impairment of Goodwill | - | - | - | -21.42 | - | - |
Gain (Loss) on Sale of Investments | - | - | 3.29 | - | - | - |
Asset Writedown | - | - | - | -3 | - | - |
Pretax Income | 143.69 | 121.89 | -39.56 | -270.03 | 227.35 | 196.46 |
Income Tax Expense | 16.91 | 6.07 | -1.51 | 2.6 | 53.48 | 48.49 |
Earnings From Continuing Operations | 126.78 | 115.82 | -38.04 | -272.64 | 173.88 | 147.97 |
Minority Interest in Earnings | -0.13 | -0.09 | -0.05 | -0.01 | -0.04 | -0.04 |
Net Income | 126.65 | 115.73 | -38.1 | -272.65 | 173.84 | 147.93 |
Net Income to Common | 126.65 | 115.73 | -38.1 | -272.65 | 173.84 | 147.93 |
Net Income Growth | 102.98% | - | - | - | 17.51% | 9.47% |
Shares Outstanding (Basic) | 847 | 570 | 570 | 564 | 572 | 577 |
Shares Outstanding (Diluted) | 847 | 570 | 570 | 564 | 572 | 577 |
Shares Change | 49.10% | - | 1.12% | -1.46% | -0.88% | - |
EPS (Basic) | 0.15 | 0.20 | -0.07 | -0.48 | 0.30 | 0.26 |
EPS (Diluted) | 0.15 | 0.20 | -0.07 | -0.48 | 0.30 | 0.26 |
EPS Growth | 34.82% | - | - | - | 17.09% | 11.40% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 48.03 | 118.51 | -86.76 | -44.44 | 129.63 | 44.44 |
Free Cash Flow Per Share | 0.06 | 0.21 | -0.15 | -0.08 | 0.23 | 0.08 |
Dividend Per Share | - | - | - | - | 0.107 | 0.069 |
Dividend Growth | - | - | - | - | 54.70% | - |
Gross Margin | 69.47% | 68.11% | 62.14% | 56.21% | 76.98% | 79.74% |
Operating Margin | 15.11% | 15.14% | 2.31% | -34.67% | 32.12% | 34.26% |
Profit Margin | 12.89% | 12.94% | -7.33% | -51.83% | 23.83% | 24.89% |
Free Cash Flow Margin | 4.89% | 13.25% | -16.69% | -8.45% | 17.77% | 7.48% |
EBITDA | 155.37 | 140.42 | 16.6 | -175.19 | 237.89 | 206.04 |
EBITDA Margin | 15.82% | 15.70% | 3.19% | -33.31% | 32.61% | 34.67% |
D&A For EBITDA | 6.9 | 4.97 | 4.57 | 7.2 | 3.54 | 2.42 |
EBIT | 148.47 | 135.45 | 12.03 | -182.39 | 234.35 | 203.62 |
EBIT Margin | 15.11% | 15.14% | 2.31% | -34.67% | 32.12% | 34.26% |
Effective Tax Rate | 11.77% | 4.98% | - | - | 23.52% | 24.68% |